Author

H. Golding

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Assay:proteomics· 3 Organism:non-human primate· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

S. Khurana· 4 shared A. Eaton· 2 shared A. Newman· 2 shared B. F. Haynes· 2 shared B. M. Nagata· 2 shared C. T. DeMarco· 2 shared D. C. Montefiori· 2 shared D. Li· 2 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

S. Khurana

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primates

R. D. Malewana, V. Stalls, A. May, X. Lu, D. R. Martinez, A. Schafer, D. Li, M. Barr, L. L. Sutherland, E. Lee, R. Parks, W. E. Beck, A. Newman, K. W. Bock, M. Minai, , K. O. Saunders

Non-stabilized SARS-CoV-2 Spike mRNA vaccination in macaques induces B cell lineages targeting conserved epitopes on Omicron variants or cross-neutralizing epitopes on Sarbecoviruses.

bioRxiv · Dec 18, 2023 · PreprintImmunology

Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine

D. Li, D. R. Martinez, A. Schäfer, H. Chen, M. Barr, L. L. Sutherland, E. Lee, R. Parks, D. Mielke, W. Edwards, A. Newman, K. W. Bock, M. Minai, B. M. Nagata, M. Gagne, , B. F. Haynes

This study shows a nanoparticle vaccine induces broad neutralizing antibodies against multiple SARS-CoV-2 variants and protects non-human primates and mice from viral challenges.

bioRxiv · Jan 26, 2022Immunology

Reduced neutralization of SARS-CoV-2 variants by convalescent plasma and hyperimmune intravenous immunoglobulins for treatment of COVID-19

J. Tang, Y. Lee, S. Ravichandran, G. Grubbs, C. Huang, C. Stauft, T. Wang, B. Golding, H. Golding, S. Khurana

This study evaluates the neutralization capacity of hyperimmune immunoglobulins and convalescent plasma against SARS-CoV-2 and its variants, finding reduced effectiveness against certain variants with hCoV-2IG showing better cross-neutralization than convalescent plasma.

bioRxiv · Mar 19, 2021Immunology

Antibody repertoire induced by SARS-CoV-2 spike protein immunogens

S. Ravichandran, E. M. Coyle, L. Klenow, J. Tang, G. Grubbs, S. Liu, T. Wang, H. Golding, S. Khurana

This study evaluates antibody responses to different SARS-CoV-2 spike protein antigens in rabbits, finding that the RBD antigen elicited higher affinity and titer neutralizing antibodies.

bioRxiv · May 12, 2020Microbiology